Mattiuzzi Camilla, Lippi Giuseppe
Service of Clinical Governance, Provincial Agency for Social and Sanitary Services, 38123 Trento, Italy.
Section of Clinical Biochemistry and School of Medicine, University of Verona, 37134 Verona, Italy.
Vaccines (Basel). 2023 Jan 18;11(2):213. doi: 10.3390/vaccines11020213.
We analyzed coronavirus disease 2019 (COVID-19) vaccine efficacy in older persons who received the second booster compared to unvaccinated people and those receiving only a single COVID-19 vaccine booster.
We collected information on vaccine efficacy from the ongoing Italian nationwide COVID-19 vaccination campaign in subjects aged 80 years or older from official data published by the Italian National Institute of Health.
The second vaccine booster maintained high effectiveness against adverse COVID-19 outcomes such as hospitalization, intensive care unit admission and death (i.e., between 77 and 86%), and also showed around 10% higher efficacy than the single booster. Nonetheless, the efficacy of the second vaccine booster declined over time, decreasing by 33-46% when assessed at >120 days from administration.
The results of our ad interim analysis of the ongoing Italian nationwide COVID-19 vaccination campaign suggest that regular boosting with COVID-19 vaccines may be advisable in older persons.
我们分析了与未接种疫苗者以及仅接种一剂新冠病毒疾病（COVID-19）疫苗加强针者相比，接种第二剂加强针的老年人中COVID-19疫苗的效力。
我们从意大利国家卫生研究院公布的官方数据中，收集了意大利正在进行的全国性COVID-19疫苗接种活动中80岁及以上受试者的疫苗效力信息。
第二剂疫苗加强针在预防COVID-19不良后果（如住院、重症监护病房收治和死亡）方面保持了较高效力（即77%至86%），并且比单剂加强针的效力高出约10%。尽管如此，第二剂疫苗加强针的效力会随着时间推移而下降，在接种后>120天进行评估时，效力下降了33%至46%。
我们对意大利正在进行的全国性COVID-19疫苗接种活动的中期分析结果表明，建议老年人定期接种COVID-19疫苗加强针。
Zotero 插件